Fiera Capital (Canada)
ALNY icon

Fiera Capital (Canada)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fiera Capital (Canada)’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.06M Sell
3,524
-75,298
-96% -$22.7M ﹤0.01% 317
2026
Q1 		$26.1M Buy
78,822
+8,102
+11% +$2.76M 0.09% 171
2025
Q4 		$28.1M Buy
70,720
+16,916
+31% +$7.49M 0.09% 161
2025
Q3 		$24.5M Buy
53,804
+26,061
+94% +$10.6M 0.08% 158
2025
Q2 		$9.05M Buy
27,743
+10,531
+61% +$2.91M 0.03% 193
2025
Q1 		$4.65M Buy
17,212
+1,242
+8% +$319K 0.02% 231
2024
Q4 		$3.76M Buy
+15,970
New +$4.2M 0.01% 232
2021
Q2 		– Sell
-3,700
Closed -$522K – 574
2021
Q1 		$522K Buy
3,700
+185
+5% +$27.8K ﹤0.01% 475
2020
Q4 		$457K Buy
3,515
+800
+29% +$107K ﹤0.01% 541
2020
Q3 		$395K Sell
2,715
-340
-11% -$48.3K ﹤0.01% 500
2020
Q2 		$452K Buy
+3,055
New +$412K ﹤0.01% 491

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fiera Capital (Canada)'s ALNY Position: Q2 2026 in Review

Fiera Capital (Canada) reduced its Alnylam Pharmaceuticals (ALNY) stake by 96% in Q2 2026, selling an estimated $22.7M and leaving 3,524 shares worth $1.06M. The position accounts for ﹤0.01% of the portfolio, ranked #317.

Fiera Capital (Canada) first reported a position in ALNY in Q2 2020 and has held it in 11 quarters since. The position peaked at $28.1M in Q4 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Fiera Capital (Canada) held 3,524 shares of Alnylam Pharmaceuticals worth $1.06M as of Q2 2026.
  • Fiera Capital (Canada) sold 75,298 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $22.7M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Fiera Capital (Canada)'s portfolio in Q2 2026, its #317 holding.
  • Fiera Capital (Canada) first reported a position in Alnylam Pharmaceuticals in Q2 2020 and has held it in 11 quarters since.
  • Fiera Capital (Canada)'s Alnylam Pharmaceuticals position peaked at $28.1M in Q4 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Fiera Capital (Canada)'s 13F filing for Q2 2026, filed 7 Aug 2026.